Integrative Genomic Analysis Identifies Novel Causal Genes of Hodgkin’s and Non-Hodgkin’s Lymphoma DOI

Patrick Shi,

Ancha Baranova, Hongbao Cao

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 24, 2025

Abstract Background The genetic mechanisms underlying non-Hodgkin lymphoma (NHL) and Hodgkin (HL) remain understudied. While numerous genes associated with these lymphoid tumors have been identified, little research has focused on the networks that directly drive NHL HL pathogenesis. Methods We conducted integrative genomic analyses, including a transcriptome-wide association study (TWAS), proteome-wide (PWAS), summary-data-based Mendelian randomization (SMR), to identify causal for HL. TWAS PWAS were performed using FUSION software by integrating GWAS data gene protein expression weights from large-scale datasets. SMR analysis utilized cis-eQTL assess relationships between risk. Associations deemed significant at p < 0.05. Results identified 106 proteins 67 revealed 172 linked risk 448 Finally, highlighted 270 risk; there was no evidence of heterogeneity in HEIDI test, which supports pleiotropic effects. Key influence include KRT1, ERAP2, RMDN1, FAS, C5, while UNC5B as Locus effect plots used validate findings highlighting variants risks. Conclusion In this study, KRT1, ERAP2, RMDN1, FAS, C5, potential factors risk, underscoring such immune modulation tumor suppression providing insights into future therapeutic targets.

Язык: Английский

Advances in primary large B-cell lymphoma of immune-privileged sites DOI Creative Commons
Wang Liao,

M. Guo,

Shuling Hou

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Фев. 26, 2025

Primary large B-cell lymphoma of immune-privileged sites (IP-LBCL) encompasses a spectrum relatively rare aggressive lymphomas, such as primary central nervous system (PCNSL), testicular (PTL), and vitreoretinal (PVRL). Macroscopically, the development IPI-LBCL may be associated with dysfunction meningeal lymphatic vessels (mLVs) perivascular channel formed by astrocytes. Microscopically, mutation in MYD88 CD79B genes plays pivotal role pathogenesis IP-LBCL. Pathological examination remains cornerstone for establishing diagnosis Moreover, traditional imaging is now supplemented suite advanced diagnostic methods, including cytological, genetic, immunological, multiple omics, molecular biological, which collectively enhance accuracy Despite these advancements, high recurrence rates attendant mortality pose significant challenges to achieving long-term survival IP-LBCL patients. However, emergence novel therapeutic agents, Bruton's tyrosine kinase inhibitors (BTKi), immune checkpoint inhibitors, immunomodulators, anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy, has offered promising new avenues treatment IP-LBCL, demonstrating remarkable anti-tumor efficacy recent years. This review delves into epidemiology, mechanisms, approaches, strategies, prognosis factors It meticulously examines parallels divergences between National Comprehensive Cancer Network (NCCN) European Society Medical Oncology (ESMO) guidelines, enhancing professional comprehension complexities inherent

Язык: Английский

Процитировано

0
In the era of targeted therapy and immunotherapy: advances in the treatment of large B-cell lymphoma of immune-privileged sites DOI Creative Commons
Haotian Wang, Ying Zhang,

Xin Wan

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 1, 2025

Primary large B-cell lymphomas of immune-privileged sites (IP-LBCLs) include primary central nervous system lymphoma (PCNSL), vitreoretinal (PVRL), and testicular (PTL). These tumors not only have a unique anatomical distribution but also exhibit specific biological clinical characteristics. Given the high overlap between intravascular (IVLBCL) IP-LBCLs, fact that IVLBCL is confined to microenvironment, currently included in category IP-LBCLs. IP-LBCLs are associated with suboptimal prognosis. However, advancements biomarker detection technologies facilitated novel therapeutic approaches for this disease entity. This review aims summarize analyze latest research progress focus on new treatment strategies era targeted therapy immunotherapy. It intended further understand characteristics, treatment, disease.

Язык: Английский

Процитировано

0
Integrative Genomic Analysis Identifies Novel Causal Genes of Hodgkin’s and Non-Hodgkin’s Lymphoma DOI

Patrick Shi,

Ancha Baranova, Hongbao Cao

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 24, 2025

Abstract Background The genetic mechanisms underlying non-Hodgkin lymphoma (NHL) and Hodgkin (HL) remain understudied. While numerous genes associated with these lymphoid tumors have been identified, little research has focused on the networks that directly drive NHL HL pathogenesis. Methods We conducted integrative genomic analyses, including a transcriptome-wide association study (TWAS), proteome-wide (PWAS), summary-data-based Mendelian randomization (SMR), to identify causal for HL. TWAS PWAS were performed using FUSION software by integrating GWAS data gene protein expression weights from large-scale datasets. SMR analysis utilized cis-eQTL assess relationships between risk. Associations deemed significant at p < 0.05. Results identified 106 proteins 67 revealed 172 linked risk 448 Finally, highlighted 270 risk; there was no evidence of heterogeneity in HEIDI test, which supports pleiotropic effects. Key influence include KRT1, ERAP2, RMDN1, FAS, C5, while UNC5B as Locus effect plots used validate findings highlighting variants risks. Conclusion In this study, KRT1, ERAP2, RMDN1, FAS, C5, potential factors risk, underscoring such immune modulation tumor suppression providing insights into future therapeutic targets.

Язык: Английский

Процитировано

0